Daily Respiratory Research Analysis
Three impactful respiratory studies emerged: a randomized trial shows closed-loop automated oxygen control shortens ventilation and reduces BPD in preterm infants; mechanistic work in Science Translational Medicine reveals 5‑methylcytidine suppresses RIG‑I–driven reactogenicity in self‑amplifying RNA vaccines; and a multicenter RCT finds NHFOV lowers reintubation versus CPAP/NIPPV after extubation in severe meconium aspiration syndrome.
Summary
Three impactful respiratory studies emerged: a randomized trial shows closed-loop automated oxygen control shortens ventilation and reduces BPD in preterm infants; mechanistic work in Science Translational Medicine reveals 5‑methylcytidine suppresses RIG‑I–driven reactogenicity in self‑amplifying RNA vaccines; and a multicenter RCT finds NHFOV lowers reintubation versus CPAP/NIPPV after extubation in severe meconium aspiration syndrome.
Research Themes
- Automated oxygen titration and neonatal respiratory outcomes
- RNA vaccine engineering to modulate innate sensing and reactogenicity
- Optimizing noninvasive ventilation post-extubation in neonatal lung disease
Selected Articles
1. Closed-loop automated oxygen control in preterm ventilated infants: a randomised controlled trial.
In a randomized controlled trial of 69 ventilated preterm infants, closed-loop automated oxygen control significantly reduced the duration of mechanical ventilation and supplemental oxygen versus manual control, and lowered BPD incidence. CLAC also increased time within SpO2 targets while reducing hypoxemia/hyperoxemia exposure.
Impact: Demonstrates clinically meaningful benefits of automated oxygen titration, including BPD reduction—a key neonatal outcome—supporting a shift toward intelligent closed-loop control in NICUs.
Clinical Implications: Closed-loop oxygen control can be considered to standardize FiO2 titration, increase time in target SpO2 range, and potentially reduce ventilation days, oxygen exposure, and BPD risk. Implementation requires validation in multicenter settings and integration into NICU workflows.
Key Findings
- CLAC reduced median ventilation duration from 40 to 11 days (p=0.027).
- CLAC shortened supplemental oxygen duration (33 vs 47 days; p=0.031).
- BPD incidence at 36 weeks PMA was lower with CLAC (55% vs 83.9%; p=0.015).
- Time within SpO2 target (91–95%) increased; hypoxemia/hyperoxemia exposure decreased (p<0.001).
Methodological Strengths
- Randomized controlled design with prespecified primary outcome.
- Objective physiologic metrics (time-in-target SpO2, BPD) and clinically meaningful endpoints.
Limitations
- Single-center trial with modest sample size.
- Blinding not feasible; potential performance bias and need for multicenter replication.
Future Directions: Multicenter pragmatic RCTs to confirm effectiveness, assess safety across different FiO2 targets, and evaluate implementation outcomes (workflow integration, alarms, staff adoption).
OBJECTIVE: To compare the duration of mechanical ventilation between preterm infants receiving closed-loop automated oxygen control (CLAC) or manual oxygen control. DESIGN: Randomised controlled trial. SETTING: Tertiary neonatal unit in London, UK. PATIENTS: Infants (n=69) with a median (IQR) gestational age of 27.0 (25.6-29.0) weeks studied at a corrected postmenstrual age of 27.6 (25.9-29.1) weeks. INTERVENTIONS: Infants were randomised to CLAC or manual oxygen control within 48 hours of initiation of mechanical ventilation if less than 7 days of age until successful extubation. MAIN OUTCOME MEASURES: Duration of mechanical ventilation. RESULTS: The CLAC infants (n=34) compared with those who received manual control had a shorter duration of mechanical ventilation (median (range): 11 (1-57) vs 40 (3-134) days, p=0.027), a shorter duration of supplemental oxygen (median (range): 33 (0-100) vs 47 (3-335) days, p=0.031), a lower incidence of bronchopulmonary dysplasia (BPD) at 36 weeks postmenstrual age (55% vs 83.9%, p=0.015) and fewer required home oxygen (26.5% vs 51.4%, p=0.016). In the CLAC infants, the time spent in the target oxygen range (91%-95%) was increased (p<0.001) and the times spent in hypoxaemia (peripheral oxygen saturation level (SpO CONCLUSIONS: Use of CLAC in preterm, ventilated infants was associated with improved achievement of oxygen saturation targets, shorter durations of mechanical ventilation and supplemental oxygen treatment and a lower incidence of BPD. These results need to be replicated in larger multicentre studies before any change in routine practice could be recommended. TRIAL REGISTRATION NUMBER: NCT05030337.
2. Incorporation of 5-methylcytidine alleviates RIG-I-mediated innate immune responses to a self-amplifying RNA vaccine.
5‑methylcytidine modification of saRNA abrogates RIG‑I sensing in plasmacytoid dendritic cells, reducing type I IFN–driven reactogenicity while sustaining antigen expression and adaptive immunity. Distinct sensing of modified saRNA by macrophages suggests safe immunostimulation can be preserved despite reduced pDC activation.
Impact: Provides mechanistic evidence for chemically modified saRNA to decouple reactogenicity from immunogenicity, informing next-generation respiratory vaccine design and dosing.
Clinical Implications: Supports clinical development of 5mC-modified saRNA vaccines to reduce systemic reactogenicity without compromising protection, potentially improving tolerability and uptake in mass vaccination campaigns.
Key Findings
- 5mC incorporation prolongs and amplifies antigen expression from saRNA while suppressing type I IFN in pDCs.
- RIG‑I mediates sensing of unmodified saRNA in pDCs; 5mC abrogates this sensing.
- saRNA‑5mC preserves innate activation in macrophages via RIG‑I–independent pathways and maintains robust B and T cell responses in vivo.
Methodological Strengths
- Multi-system mechanistic approach spanning pDCs, macrophages, in vivo models, and adaptive immunity readouts.
- Clear causal link established between 5mC modification, RIG‑I sensing, interferon induction, and reactogenicity.
Limitations
- Preclinical study; human clinical correlates of reduced reactogenicity require confirmation across diverse antigens.
- Focus on SARS‑CoV‑2 RBD; generalizability to other saRNA payloads and delivery systems needs evaluation.
Future Directions: Conduct dose-ranging clinical trials comparing saRNA with and without 5mC across antigens; delineate innate sensing pathways in human APC subsets; model reactogenicity–immunogenicity trade-offs to optimize regimens.
To improve existing synthetic RNA-based vaccines, we previously developed a self-amplifying RNA (saRNA)-based vaccine expressing a membrane-anchored (TM) receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein (S-RBD-TM) and demonstrated that a low dose of this saRNA vaccine elicits robust immune responses. Moreover, a recent clinical trial with an saRNA vaccine incorporating 5-methylcytidine (5mC) (saRNA-5mC) has demonstrated reduced vaccine reactogenicity while maintaining robust humoral responses. In this study, we investigate the mechanisms by which 5mC incorporation attenuates adverse effects while maintaining immunogenicity. We found that incorporation of 5mC into the saRNA platform led to prolonged and robust expression of antigen and attenuated induction of type I interferon, a key driver of reactogenicity, specifically in plasmacytoid dendritic cells (pDCs). As a result, saRNA-5mC alleviated excessive innate immune responses in vivo without impairing B cell and T cell responses against the SARS-CoV-2 RBD. Mechanistically, we demonstrated that the detection of unmodified saRNA in pDCs was mediated by a host cytosolic RNA sensor, RIG-I, and this sensing was abolished with 5mC incorporation. In contrast, saRNA-5mC induced robust innate activation in professional antigen-presenting cells, such as macrophages, in a RIG-I-independent manner, highlighting distinct host sensing mechanisms for synthetic RNAs. Our study provides support for the potential clinical use of saRNA-5mC vaccine platforms.
3. NHFOV Versus CPAP and NIPPV for Post-Extubation Support in Severe Meconium Aspiration Syndrome.
In a multicenter RCT of severe MAS neonates, NHFOV reduced 7‑day reintubation compared with NCPAP and NIPPV and improved oxygenation/ventilation parameters. NHFOV also shortened ventilation and hospital stay and reduced device-related complications without increasing serious adverse events.
Impact: Directly informs post-extubation noninvasive respiratory support selection in a high-risk neonatal population where evidence has been limited.
Clinical Implications: For severe MAS after extubation, NHFOV may be preferred over NCPAP/NIPPV to reduce reintubation and improve gas exchange, with potential reductions in length of stay and complications.
Key Findings
- NHFOV lowered 7‑day reintubation compared with NCPAP and NIPPV.
- NHFOV achieved higher PaO2 and lower PaCO2 at 1, 12, and 24 hours post-extubation.
- Secondary outcomes (ventilation days, hospital stay, nasal trauma/abdominal distension) favored NHFOV; serious complications were similar across groups.
Methodological Strengths
- Multicenter randomized controlled design with prospective registry.
- Clear primary and secondary outcomes with serial blood gas measurements.
Limitations
- Short follow-up focused on early (7‑day) outcomes; long-term respiratory and neurodevelopmental outcomes not assessed.
- Blinding not feasible; potential for performance bias.
Future Directions: Long-term follow-up to assess respiratory morbidity and neurodevelopment; cost-effectiveness analyses and implementation studies across diverse NICU settings.
OBJECTIVE: The present study was conducted to compare the clinical efficacy of three noninvasive respiratory support strategies-nasal continuous positive airway pressure (NCPAP), noninvasive positive pressure ventilation (NIPPV), and noninvasive high-frequency oscillatory ventilation (NHFOV)-in neonates with severe meconium aspiration syndrome (MAS) following extubation. METHODS: In this multicenter randomized controlled trial, 170 neonates with severe MAS from three tertiary neonatal intensive care units in Southwest China (Jan 2025-May 2025) were randomized to receive post-extubation NCPAP (n = 56), NIPPV (n = 63), or NHFOV (n = 51). Primary outcomes were reintubation rate within 7 days and arterial blood gas parameters at 1, 12, and 24 h post-extubation. Secondary outcomes included ventilation duration, supplemental oxygen days, hospital stay, and complications including but not limited to nasal trauma, abdominal distension, among other predefined complications. The research protocol was prospectively registered in the Chinese Clinical Trial Registry (MR-50-24-057272; registration date: December 28, 2024). RESULTS: NHFOV demonstrated significantly lower reintubation rates compared to both NCPAP and NIPPV, while no difference was observed between NIPPV and NCPAP. NHFOV showed superior oxygenation with higher PaO₂ levels and lower PaCO₂ levels across all timepoints. Secondary outcomes favored NHFOV, including shorter durations of invasive ventilation, noninvasive ventilation, and hospital stay, alongside reduced complications (abdominal distension, nasal trauma). No significant differences were observed in BPD, air leaks, severe IVH, or NEC rates among groups. CONCLUSIONS: NHFOV significantly reduces reintubation rates and improves gas exchange compared to NCPAP and NIPPV in severe MAS neonates, supporting its potential as the preferred post-extubation respiratory support strategy.